Published Date: 09 May 2025
In a new study led by the UCLA Health Jonsson Comprehensive Cancer Center, investigators show that using advanced MRI imaging and targeted focal therapy can help many men with low- to intermediate-risk prostate cancer safely ...
Read Full NewsMRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.
Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.
Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.
A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.
1.
Distribution of fat could influence cancer risk, study suggests
2.
While most cancer screenings won't prolong lives, there are still good reasons to continue screening.
3.
Ignoring Colonoscopy Advice; Dry Mouth Acupuncture; Inflamed Tongue, Then Cancer.
4.
DBT Reduced Suicide Attempts in Adolescents with Bipolar Disorder.
5.
With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.
1.
Know About Lymphangioma: Symptoms, Causes, and Treatments
2.
What You Need to Know about Hairy Cell Leukemia: A Comprehensive Guide
3.
The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting
4.
Asymptomatic Thrombocytopenia: Unraveling the Enigma of Low Platelet Counts Without Symptoms
5.
ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Navigating the Complexities of Ph Negative ALL - Part VII
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation